NovaBridge Biosciences stock stood at USD 1.26 on October 16, 2026, price-earnings ratio -2.2
Published on 10/17/2026 at 22:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSValuation and trading dates
- NovaBridge Biosciences carried a price-earnings ratio of minus 2.21 on October 16, 2026.
- The stock's 52-week range was USD 1.26 to USD 5.97 as of October 16, 2026.
- NovaBridge Biosciences stock cost USD 1.26 on October 16, 2026 at 4:00 p.m. ET, down 2.33 percent versus the prior close.
- NovaBridge Biosciences is scheduled to report third-quarter 2026 results on November 12, 2026.
NovaBridge Biosciences stock carried a price-earnings ratio of minus 2.21 on October 16, 2026, while its market capitalization was USD 145.2 million. The latest Nasdaq quote was USD 1.26 on October 16, 2026 at 4:00 p.m. ET, down 2.33 percent from the prior close.
Valuation sets the frame
The negative ratio reflects the clinical-stage biotechnology company's loss-making position rather than a conventional earnings valuation. NovaBridge Biosciences describes its business as a clinical-stage platform focused on oncology and ophthalmology medicines. Its pipeline includes givastomig, ragistomig, uliledlimab and the VIS-101 ophthalmology program.
The range remains wide
The stock's 52-week range was USD 1.26 to USD 5.97 as of October 16, 2026. The latest quote therefore sat at the lower bound of that range, while the reported market capitalization was USD 145.2 million. Trading volume was 350,686 shares against an average of 390,053 shares on the same date, equal to 89.91 percent of the average.
Dates shape the calendar
The next scheduled corporate date is November 12, 2026, when NovaBridge Biosciences is expected to report third-quarter 2026 results. Barrons lists that reporting date for the company. The date gives investors the next fixed point for assessing cash use, pipeline progress and the path toward later-stage studies.
Comparison with peers
NovaBridge Biosciences (Nasdaq, USD): minus 2.33 percent, price-earnings ratio minus 2.21, market capitalization USD 145.2 million.
Madrigal Pharmaceuticals (Nasdaq, USD): minus 2.19 percent, price-earnings ratio minus 34.89, market capitalization USD 10.4 billion.
BioAge Labs (Nasdaq, USD): minus 9.53 percent, price-earnings ratio minus 2.03, market capitalization USD 182.2 million.
Closing market view
The comparison places NovaBridge Biosciences in a small-cap biotechnology group where negative earnings remain common, but the market values differ sharply. The stock stood at USD 1.26 on October 16, 2026 at 4:00 p.m. ET, down 2.33 percent versus the prior close.
NovaBridge Biosciences market data
- Company: NovaBridge Biosciences
- ISIN: US44975P1030
- Ticker: NBP
- Primary exchange: Nasdaq
- Price Nasdaq (as of October 16, 2026, 4:00 p.m. ET): USD 1.26
- Change versus prior close: minus 2.33 percent
- Market capitalization: USD 145.2 million (as of October 16, 2026)
- 52-week range: USD 1.26-5.97 (as of October 16, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 12, 2026
Market context: Market report S&P 500.
